Latest Articles

Publication Date
Obstructed Hemivagina with Ipsilateral Renal Anomaly: Radiological Diagnosis, Outcome of Surgical Management and Literature Review.

Background and Clinical Significance: Obstructed hemivagina and ipsilateral renal anomaly (OHVIRA) syndrome is a rare Müllerian duct anomaly that is frequently misdiagnosed as primary dysmenorrhea, resulting in delayed intervention and …

Published: Feb. 11, 2026, midnight
Information Needs of Women Affected by Endometriosis and Their Environment: Qualitative Results from Participatory Workshops.

Background/Objectives: Endometriosis affects ~10% of women, causing chronic pain, reduced quality of life, and, often, infertility. As endometriosis literacy and awareness are low in society and among health care providers …

Published: Feb. 11, 2026, midnight
FBXW7 suppresses cell proliferation, migration, and epithelial-mesenchymal transition in endometrioid ovarian carcinoma.

Epithelial ovarian carcinoma is a common gynecologic malignancy. Evidence from several studies suggests that subtypes of this cancer-specifically clear-cell ovarian carcinoma and endometrioid ovarian carcinoma (ENOC)-are associated with endometriosis. FBXW7 …

Published: Feb. 11, 2026, midnight
[Role of hyaluronic acid synthases in female infertility-related diseases].

The hyaluronic acid synthase (HAS) family participates in key physiological processes such as follicular development, oocyte maturation, ovulation, and embryo implantation by regulating the synthesis of hyaluronic acid, and plays …

Published: Feb. 10, 2026, midnight
Transparency only from authors? Insights from 'mysterious' retractions in obstetrics and gynecology.

Retraction of scientific papers may occur when the peer-review or publication process is compromised, even in cases where authors have no responsibility for the identified shortcomings. Using a recent case …

Published: Feb. 10, 2026, midnight
Reply of the Authors: Safety and pharmacology of AMY109, a long-acting anti-interleukin-8 antibody, for endometriosis: a double-blind, randomized phase 1 trial.

Published: Feb. 10, 2026, midnight
Comments on "Safety and pharmacology of AMY109, a long-acting anti-interleukin-8 antibody, for endometriosis: a double-blind, randomized phase 1 trial".

Published: Feb. 10, 2026, midnight
Unraveling molecular heterogeneity: a systematic review of susceptibility gene profiles in ovarian, deep infiltrating, and superficial peritoneal endometriosis.

Endometriosis is a heterogeneous gynecological disease manifesting in three distinct phenotypes: superficial peritoneal endometriosis (SUP), ovarian endometrioma (OMA), and deep infiltrating endometriosis (DIE). While Genome-Wide Association Studies (GWAS) have identified …

Published: Feb. 10, 2026, midnight
Systemic Oxidative Stress Markers in Endometriosis: Elevated Advanced Glycation End Products and Sestrin 2 in Women with Ovarian Endometrioma.

Background/Objectives: Endometriosis is a chronic inflammatory disease characterized by ectopic endometrial tissue growth and is strongly associated with oxidative stress; however, systemic biomarkers reflecting this stress response remain limited. Advanced …

Published: Feb. 10, 2026, midnight
Gut Microbiota Alterations and Reproductive Tract Dysbiosis in Endometriosis: A Systematic Review.

Background and Objectives: Endometriosis is a chronic, estrogen-dependent inflammatory disease with multifactorial pathogenesis. Increasing evidence suggests that alterations in the gut and reproductive tract microbiota may contribute to disease development, …

Published: Feb. 10, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!